Valuation dashboard for Galectin Therapeutics Inc. (GALT) with P/E N/A, P/B -1.79, EV/EBITDA -16.28 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $3.68, GALT has negative trailing earnings (P/E not meaningful) and an ROE of 24.44%. Market capitalisation stands at $242M.
Balance sheet quality for GALT: current ratio of 2.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -1.79 |
| EV / EBITDA | -16.28 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-1.86 |
| vs Current Price | -150.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| GALT | Galectin Therapeutics Inc. | $242M | 24.4% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $3.68 |
| Market Cap | $242M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | 24.44% |
| Return on Invested Capital | -174.29% |
| Return on Assets | -157.87% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALT · AURA · DMAC · DRTS · DSGN · ENGN · IMAB
Explore sector: Healthcare · Biotechnology
More sections of GALT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks